FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2963464328> ?p ?o ?g. }

• W2963464328 endingPage "614" @default.
• W2963464328 startingPage "601" @default.
• W2963464328 abstract "Spinocerebellar ataxia type 3 (SCA3) and type 1 (SCA1) are dominantly inherited neurodegenerative disorders that are currently incurable. Both diseases are caused by a CAG-repeat expansion in exon 10 of the Ataxin-3 and exon 8 of the Ataxin-1 gene, respectively, encoding an elongated polyglutamine tract that confers toxic properties to the resulting proteins. We have previously shown lowering of the pathogenic polyglutamine protein in Huntington’s disease mouse models using (CUG)7, a CAG repeat-targeting antisense oligonucleotide. Here we evaluated the therapeutic capacity of (CUG)7 for SCA3 and SCA1, in vitro in patient-derived cell lines and in vivo in representative mouse models. Repeated intracerebroventricular (CUG)7 administration resulted in a significant reduction of mutant Ataxin-3 and Ataxin-1 proteins throughout the brain of SCA3 and SCA1 mouse models, respectively. Furthermore, in both a SCA3 patient cell line and the MJD84.2 mouse model, (CUG)7 induced formation of a truncated Ataxin-3 protein species lacking the polyglutamine stretch, likely arising from (CUG)7-mediated exon 10 skipping. In contrast, skipping of exon 8 of Ataxin-1 did not significantly contribute to the Ataxin-1 protein reduction observed in (CUG)7-treated SCA1154Q/2Q mice. These findings support the therapeutic potential of a single CAG repeat-targeting AON for the treatment of multiple polyglutamine disorders. Spinocerebellar ataxia type 3 (SCA3) and type 1 (SCA1) are dominantly inherited neurodegenerative disorders that are currently incurable. Both diseases are caused by a CAG-repeat expansion in exon 10 of the Ataxin-3 and exon 8 of the Ataxin-1 gene, respectively, encoding an elongated polyglutamine tract that confers toxic properties to the resulting proteins. We have previously shown lowering of the pathogenic polyglutamine protein in Huntington’s disease mouse models using (CUG)7, a CAG repeat-targeting antisense oligonucleotide. Here we evaluated the therapeutic capacity of (CUG)7 for SCA3 and SCA1, in vitro in patient-derived cell lines and in vivo in representative mouse models. Repeated intracerebroventricular (CUG)7 administration resulted in a significant reduction of mutant Ataxin-3 and Ataxin-1 proteins throughout the brain of SCA3 and SCA1 mouse models, respectively. Furthermore, in both a SCA3 patient cell line and the MJD84.2 mouse model, (CUG)7 induced formation of a truncated Ataxin-3 protein species lacking the polyglutamine stretch, likely arising from (CUG)7-mediated exon 10 skipping. In contrast, skipping of exon 8 of Ataxin-1 did not significantly contribute to the Ataxin-1 protein reduction observed in (CUG)7-treated SCA1154Q/2Q mice. These findings support the therapeutic potential of a single CAG repeat-targeting AON for the treatment of multiple polyglutamine disorders." @default.
• W2963464328 created "2019-07-30" @default.
• W2963464328 creator A5028381176 @default.
• W2963464328 creator A5030444039 @default.
• W2963464328 creator A5037927529 @default.
• W2963464328 creator A5044350835 @default.
• W2963464328 creator A5051904745 @default.
• W2963464328 creator A5063039155 @default.
• W2963464328 creator A5066344161 @default.
• W2963464328 creator A5072282532 @default.
• W2963464328 creator A5072615914 @default.
• W2963464328 creator A5087607269 @default.
• W2963464328 creator A5091435687 @default.
• W2963464328 date "2019-09-01" @default.
• W2963464328 modified "2023-10-17" @default.
• W2963464328 title "Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide" @default.
• W2963464328 cites W1973031195 @default.
• W2963464328 cites W1973916539 @default.
• W2963464328 cites W1974132683 @default.
• W2963464328 cites W1990288633 @default.
• W2963464328 cites W2007578481 @default.
• W2963464328 cites W2011136084 @default.
• W2963464328 cites W2012389333 @default.
• W2963464328 cites W2018829484 @default.
• W2963464328 cites W2021549542 @default.
• W2963464328 cites W2023081765 @default.
• W2963464328 cites W2025295962 @default.
• W2963464328 cites W2034977002 @default.
• W2963464328 cites W2046521227 @default.
• W2963464328 cites W2052404695 @default.
• W2963464328 cites W2058543711 @default.
• W2963464328 cites W2062203120 @default.
• W2963464328 cites W2078913984 @default.
• W2963464328 cites W2085069351 @default.
• W2963464328 cites W2100729221 @default.
• W2963464328 cites W2102312711 @default.
• W2963464328 cites W2107941452 @default.
• W2963464328 cites W2108570063 @default.
• W2963464328 cites W2126877059 @default.
• W2963464328 cites W2127133389 @default.
• W2963464328 cites W2135566609 @default.
• W2963464328 cites W2157458103 @default.
• W2963464328 cites W2161520201 @default.
• W2963464328 cites W2162932379 @default.
• W2963464328 cites W2167215915 @default.
• W2963464328 cites W2300951885 @default.
• W2963464328 cites W2342089554 @default.
• W2963464328 cites W2396101409 @default.
• W2963464328 cites W2515424430 @default.
• W2963464328 cites W2529432601 @default.
• W2963464328 cites W2587247473 @default.
• W2963464328 cites W2726830914 @default.
• W2963464328 cites W2743090929 @default.
• W2963464328 cites W2747198643 @default.
• W2963464328 cites W2765483614 @default.
• W2963464328 cites W2789114047 @default.
• W2963464328 cites W2803976753 @default.
• W2963464328 cites W2898693092 @default.
• W2963464328 cites W2906903526 @default.
• W2963464328 cites W2919539529 @default.
• W2963464328 cites W33753759 @default.
• W2963464328 cites W4252368281 @default.
• W2963464328 doi "https://doi.org/10.1016/j.omtn.2019.07.004" @default.
• W2963464328 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6695277" @default.
• W2963464328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31394429" @default.
• W2963464328 hasPublicationYear "2019" @default.
• W2963464328 type Work @default.
• W2963464328 sameAs 2963464328 @default.
• W2963464328 citedByCount "39" @default.
• W2963464328 countsByYear W29634643282019 @default.
• W2963464328 countsByYear W29634643282020 @default.
• W2963464328 countsByYear W29634643282021 @default.
• W2963464328 countsByYear W29634643282022 @default.
• W2963464328 countsByYear W29634643282023 @default.
• W2963464328 crossrefType "journal-article" @default.
• W2963464328 hasAuthorship W2963464328A5028381176 @default.
• W2963464328 hasAuthorship W2963464328A5030444039 @default.
• W2963464328 hasAuthorship W2963464328A5037927529 @default.
• W2963464328 hasAuthorship W2963464328A5044350835 @default.
• W2963464328 hasAuthorship W2963464328A5051904745 @default.
• W2963464328 hasAuthorship W2963464328A5063039155 @default.
• W2963464328 hasAuthorship W2963464328A5066344161 @default.
• W2963464328 hasAuthorship W2963464328A5072282532 @default.
• W2963464328 hasAuthorship W2963464328A5072615914 @default.
• W2963464328 hasAuthorship W2963464328A5087607269 @default.
• W2963464328 hasAuthorship W2963464328A5091435687 @default.
• W2963464328 hasBestOaLocation W29634643281 @default.
• W2963464328 hasConcept C104317684 @default.
• W2963464328 hasConcept C143065580 @default.
• W2963464328 hasConcept C153911025 @default.
• W2963464328 hasConcept C166252455 @default.
• W2963464328 hasConcept C169760540 @default.
• W2963464328 hasConcept C180754005 @default.
• W2963464328 hasConcept C194583182 @default.
• W2963464328 hasConcept C2777616661 @default.
• W2963464328 hasConcept C2777748165 @default.
• W2963464328 hasConcept C2778776201 @default.
• W2963464328 hasConcept C2779500118 @default.

• next